On July 17, 2025, Eric D. Shaff resigned as CEO of Seres Therapeutics, effective July 31, 2025, while Marella Thorell and Thomas J. DesRosier were appointed as Co-CEOs starting August 1, 2025. The company agreed to pay a $500,000 bonus each to the new Co-CEOs, contingent on their continued employment.